Track topics on Twitter Track topics that are important to you
Stephen Farr and Jonathan Rigby, two members of Zogenix's founding team, talk to Fintan Walton about setting up the company and the novel, needle-free injection technology platform on which it is based. They discuss Zogenix's business model for becoming a speciality pharmaceutical company and outline their plan to drive their lead product to an NDA filing. Stephen and Jonathan provide an overview of the Intraject® technology and of the company's plan to form strategic partnerships in order to produce novel products and add value to existing therapies. Zogenix's plan to develop its own specialist sales force for the US market as well as its intention to seek a co-promotion partner for entrance into Europe are also covered.NEXT ARTICLE
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...